Ikerian

RetinAI is a healthcare technology company specializing in AI-driven software solutions that harmonize and analyze unstructured medical data to improve patient outcomes. Operating primarily in the healthcare sector, RetinAI serves medical professionals, researchers, and healthcare organizations by providing a comprehensive data platform. This platform allows users to manage, access, and analyze medical data from various formats, including DICOM-compliant and proprietary formats, anytime and anywhere. The company's business model revolves around offering a subscription-based service for its data platform, which includes features like data collection, processing, visualization, and global collaboration. By leveraging AI, RetinAI extracts valuable insights about disease progression and treatment outcomes, enabling more informed decision-making in healthcare. The company generates revenue through subscriptions and partnerships with healthcare organizations and research institutions. RetinAI has successfully raised a total of USD 11.66M across Seed, Series A, and Series A Extension funding rounds, with strategic investments from Topcon Healthcare and Kantonalbank ZKB.

Keywords: AI-driven, medical data, healthcare technology, patient outcomes, data platform, disease insights, subscription-based, global collaboration, DICOM-compliant, research institutions.